Contineum Therapeutics (CTNM) Financials

Contineum Therapeutics (NASDAQ: CTNM) remains a pre-revenue clinical-stage biotech with substantial cash, but ongoing losses and cash burn continue to define the story. Over the last several years, the company has generated no revenue, consistently reported operating losses, and relied on its balance sheet and capital markets to fund research and development. The latest quarter shows a very large cash position, which is a key positive, but the operating cash burn is still significant.

• Strong liquidity position: As of Q1 2026, CTNM held $20.2 million in cash and $226.2 million in short-term investments, for total current assets of about $253.0 million.
• Minimal debt burden: Total liabilities were only $11.3 million in Q1 2026, leaving the company with a very clean balance sheet.
• Large equity cushion: Total common equity stood at $250.0 million in Q1 2026, providing meaningful financial flexibility.
• Investments are still generating income: Interest and investment income was $2.5 million in Q1 2026, helping offset some operating losses.
• Revenue remains zero: CTNM reported no revenue in every quarter shown, so the company is still fully dependent on clinical progress and financing rather than commercial sales.
• Operating expenses remain elevated: Q1 2026 operating expenses were $16.9 million, with R&D at $11.6 million and SG&A at $5.3 million, reflecting continued investment in development and overhead.
• Net losses remain persistent: The company posted a Q1 2026 net loss of $14.5 million, only modestly improved from $15.2 million in Q4 2025 and $16.0 million in Q2 2025.
• Share count has increased over time: Basic weighted-average shares were 37.3 million in Q1 2026 versus 25.9 million in Q1 2025, indicating dilution from equity issuance.
• Operating cash burn is substantial: CTNM used $16.3 million in operating cash in Q1 2026, following $13.0 million in Q4 2025 and $15.7 million in Q2 2025.
• Investing cash outflows remain heavy: The company invested heavily in short-term securities, leading to $39.3 million of net investing cash outflow in Q1 2026.
• Retained losses continue to deepen: Retained earnings were $(191.8) million in Q1 2026, reflecting years of accumulated losses.
• Equity financing has been important historically: Cash flow data show significant common equity issuance in late 2025, which helped fund operations but also points to future dilution risk.

Trend summary: Compared with 2024, CTNM has grown its balance sheet dramatically, moving from $123.6 million in assets at Q1 2024 to $261.3 million in Q1 2026. That improvement is driven mainly by cash raised and invested rather than business revenue. The company’s core financial pattern is unchanged: no sales, recurring operating losses, and dependence on its cash and investment portfolio to fund a long development runway.

Bottom line: CTNM’s balance sheet currently looks strong for a biotech, and that lowers near-term financing pressure. But investors should keep in mind that the company is still burning cash with no revenue, so the stock’s long-term outcome will likely depend on clinical execution and eventual commercialization or partnership success.